Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Anti-SARS-CoV-2 spike monoclonal antibody

Sotrovimab

Brand names: Xevudy

Sotrovimab is a recombinant human monoclonal antibody used for treatment of COVID-19 in eligible high-risk patients.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It binds a conserved epitope on the SARS-CoV-2 spike protein, neutralising the virus and limiting its ability to infect host cells.

Prescribing in practice

  • Infusion-related and hypersensitivity reactions, including anaphylaxis, can occur, so give by intravenous infusion with monitoring and resuscitation facilities available.
  • Activity depends on the circulating variant, so use should follow current national recommendations on susceptibility.
  • It is reserved for patients meeting national high-risk eligibility criteria.

Monitoring

Observe the patient during and for a period after the infusion for hypersensitivity or infusion reactions.

Counselling the patient

  • This treatment is given as a single drip in a monitored setting.
  • Report any rash, breathlessness, dizziness or chest tightness during or after the infusion.
  • It is offered to people at higher risk of severe COVID-19.

Evidence & guidelines

Sotrovimab use is guided by MHRA authorisation and national recommendations, with effectiveness dependent on circulating SARS-CoV-2 variants.

Reference: NICE TA878; UKHSA; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways